{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-116346","form_type":"8-K","ticker":"ZBIO","cik":"0001953926","company_name":"Zenas BioPharma, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.429606+00:00","generated_at":"2026-05-30T02:20:07.343686+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Zenas Q3 2024: Net loss $38.6M; raised $258.7M IPO; obexelimab INDIGO topline by end 2025","bullets":["Completed IPO raising $258.7M gross proceeds; cash $386.8M to fund into Q4 2026.","Phase 3 INDIGO (IgG4-RD) completed enrollment; topline results expected by end 2025.","Initiated Phase 2 MoonStone (RMS) and SunStone (SLE); MoonStone results Q3 2025, SunStone topline H1 2026.","Net loss $38.6M vs net income $35.6M (prior year had BMS collaboration); R&D $33.5M vs $9.4M.","Appointed CCO Orlando Oliveira and CLO Jeff Held; out-licensed ZB005 for upfront and milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-116346","json":"https://secwatch.observer/filing/0001104659-24-116346.json","markdown":"https://secwatch.observer/filing/0001104659-24-116346.md","text":"https://secwatch.observer/filing/0001104659-24-116346.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1953926/000110465924116346/0001104659-24-116346-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1953926/000110465924116346/tm2427736d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:20:07.343686+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}